Summit Therapeutics Inc Ordinary Shares SMMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SMMT is a good fit for your portfolio.
News
-
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
-
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
-
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
-
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
-
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
-
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
Trading Information
- Previous Close Price
- $3.59
- Day Range
- $3.44–3.62
- 52-Week Range
- $1.30–5.22
- Bid/Ask
- $3.51 / $3.65
- Market Cap
- $2.49 Bil
- Volume/Avg
- 1.4 Mil / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 105
- Website
- https://www.smmttx.com
Comparables
Valuation
|
Metric
|
SMMT
|
ICVX
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 32.42 | 3.30 | 3.56 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SMMT
ICVX
EWTX
Financial Strength
|
Metric
|
SMMT
|
ICVX
|
EWTX
|
|---|---|---|---|
Quick Ratio | 9.17 | 17.59 | 18.98 |
Current Ratio | 9.30 | 18.06 | 19.50 |
Interest Coverage | −36.99 | — | — |
Quick Ratio
SMMT
ICVX
EWTX
Profitability
|
Metric
|
SMMT
|
ICVX
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −25.32% | −29.30% | −24.36% |
Return on Equity (Normalized) | −71.75% | −31.87% | −25.87% |
Return on Invested Capital (Normalized) | −24.62% | −34.69% | −29.82% |
Return on Assets
SMMT
ICVX
EWTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jfjtttpz | Xwblt | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sbylwqbh | Xjllt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rxskmhtj | Hrpqrg | $99.5 Bil | |
MRNA
| Moderna Inc | Wcxqhrbx | Mkww | $38.8 Bil | |
ARGX
| argenx SE ADR | Fqlszvwrk | Kwfh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qhhwgzj | Xbj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kxmkqql | Dyfld | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zxgkxpkw | Bvmfxy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qbmhkwsmq | Lzvvcf | $12.5 Bil | |
INCY
| Incyte Corp | Gwdfncgw | Mhtfxz | $11.6 Bil |